Cell and gene therapy

FDA headquarters
#Cell and gene therapy #FDA #Personalised medicine #Regulatory

FDA introduces new pathway for personalised medicines

The US Food and Drug Administration (FDA) has laid out the process and requirements of its novel plausible mechanism pathway for personalised medicine in a New England Journal of Medicine (NEJM) editorial by Commissioner Martin Makary and Deputy Vinay Prasad.  The editorial acknowledges that personalised therapies “challenge traditional models of… Read More

#News #Regulatory #Trending News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Webinar: The latest advances in advanced therapies discovery

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this free webinar on 25 September will explore developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Register now to hear from the CGT experts

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this free webinar on 25 September will explore developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#Cell and gene therapy #Drug discovery #Mental health #National Institute for Health and Care Excellence (NICE)

This week in drug discovery 8-12 September

News round-up for 8-12 September by DDW Editor Reece Armstrong. Fast-track designations by the FDA, clinical trials to advance mental health and pharma team-ups to bring innovations to market are just some of the stories in this week’s news round-up. The top stories FDA fast-tracks Sanofi’s AMD gene therapy… Read More

#News

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Webinar: Challenges and solutions in CGT drug discovery

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this webinar explores developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. In… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Webinar: Experts explore developments in CGT drug discovery

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this webinar explores developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. In… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Watch now: Breaking barriers in cell and gene therapy

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this webinar explores developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. In… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy

Breaking barriers in cell and gene therapy

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this free webinar will explore developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#Webinars

#Advanced Therapies #Biomanufacturing #Cell and gene therapy #Drug discovery #Manufacturing

New DDW Highlights podcast: 28 July 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Following the recent news that the FDA rejected Ultragenyx Pharmaceutical’s gene therapy due to manufacturing concerns,… Read More

#News

#Advanced Therapies #Biomanufacturing #Cell and gene therapy #Drug discovery #Manufacturing

This week in drug discovery (21-25 July) 

News round-up for 21-25 July by DDW Senior Digital Content Editor Diana Turner. Following the recent news that the FDA rejected Ultragenyx Pharmaceutical’s gene therapy due to manufacturing concerns, manufacturing has dominated the headlines this week, particularly significant investment in facilities in the US, and new guidelines… Read More

#News

Cell and gene therapy
#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Manufacturing #MHRA #UK

Landmark UK legislation improves access to personalised therapies

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has brought in new regulations designed to make it easier for personalised cancer treatments and gene therapies to be made where patients are treated.  The new legislation ‘The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations… Read More

#News #Trending News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Cellular Origins #Manufacturing #Resolution Therapeutics

Consortium tackles the challenge of scaling CGT manufacturing

Cellular Origins, the Cell and Gene Therapy Catapult (CGT Catapult), and Resolution Therapeutics have formed a consortium to deliver a fully automated, scalable cell therapy manufacturing platform.  The consortium has been awarded a cross-industry Smart Grant of £1 million from Innovate UK, the UK’s national innovation agency. Read More

#News

#Advanced Therapies #Cell and gene therapy #Drug discovery #Gene therapy

New DDW Highlights podcast: 21 July 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s news highlights reflect the incredible levels of innovation and investment, but also the… Read More

#News

#Advanced Therapies #Cell and gene therapy #Drug discovery #Gene therapy

This week in drug discovery (14-18 July) 

News round-up for 14-18 July by DDW Senior Digital Content Editor Diana Turner. This week’s news highlights reflect the incredible levels of innovation and investment, but also the hurdles to overcome, in developing gene therapies – breakthrough treatments in many genetic diseases that can bring their own unique… Read More

#News

#ASGCT #Cell and gene therapy #Events #ISCT

Industry insights from Q2 2025 events

The International Society for Cell & Gene Therapy (ISCT)’s conference took place from 7-10 May, just before the American Society of Gene & Cell Therapy (ASGCT)’s conference from 13-17 May, both in New Orleans. Here, industry experts provided DDW’s Megan Thomas with insight from the events. Allogeneic cell therapies Lindsay… Read More

#Exclusive Content

#Cell and gene therapy #Circio Holding #circular RNAs #Collaboration #NeoRegen Biotech #RNA

NeoRegen and Circio progress circular RNA research collaboration

Circio Holding and NeoRegen Biotech have signed a second Material Transfer Agreement (MTA) to advance their ongoing collaboration for the delivery of circular RNA (circRNA) expression-based therapeutics.   The collaboration now is progressing to the in vivo preclinical stage following successful proof-of-concept (POC) results from in vitro studies.  The collaboration… Read More

#Business & Investment #News